Expression of epidermal growth factor receptor (EGFR) was found in 60-75% of colorectal carcinomas. Based on this, many studies have demonstrated the efficiency of monoclonal Abs (mAbs) in targeting the EGFR, such as cetuximab and panitumumab, in metastatic colorectal cancer (mCRC) patients. Addition of cetuximab to irinotecan-based chemotherapy significantly improved the response rate and the progression-free survival (PFS) when compared with Cetuximab mAb alone (22.9% vs. 10.8% and 4.1 vs. 1.5 months, respectively) [1] .
Van Cutsem et al. [2, 3] reported that in chemonaive mCRC patients, the addition of anti-EGFR to irinotecan-based chemotherapy led to an 8.2% increase in the objective response (46.8% vs. 38.4%), a 0.9-month increase in the progression free survival (PFS) (8.9 vs. 8 months) and a 1.3-month increase in the overall survival (19.9 vs. 18.6 months). Initially, the use of anti-EGFR mAbs was restricted to mCRC patients with expression of EGFR that was detectable using immunohistochemistry. However, due to the lack of immunohistochemistry predictive value and the variable clinical response, more reliable predictive markers of the response to anti-EGFR mAbs are needed [4] . Two types of molecular predictive markers have been investigated. The first is somatic mutations in EGFR pathway effectors, such as RAS-RAF-MAPK and PI3K-Akt-PTEN. Amplification of EGFR and overexpression of EGFR ligands are associated with sensitivity to anti-EGFR mAbs, but the mutations of BRAF and PIK3A and the loss of PTEN expression are associated with resistance to anti-EGFR mAbs [2, 5] . The second is germline polymorphisms of genes involved in the EGFR path-
